Skip to content

Clinical trials

Chronic Pain trials in Canada with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Chronic Pain Phase: Not applicable Country / region: Canada Clear all

112 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20051
20061
20082
20093
20102
20111
20125
20133
20145
20153
20164
20177
20188
20199
20208
20218
20229
202312
20245
202511
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed61
Unknown status17
Recruiting16
Withdrawn7
Not yet recruiting5
Active, not recruiting3
Terminated3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University Health Network, Toronto10
Université de Sherbrooke9
Ottawa Hospital Research Institute8
McMaster University6
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's5
The Hospital for Sick Children5
University of Manitoba5
Laval University4
Women's College Hospital4
Ciusss de L'Est de l'Île de Montréal3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Chronic Pain112
Pain16
Agnosia9
Postoperative Pain8
Anxiety Disorders7
Acute Pain4
Fibromyalgia4
Migraine Disorders4
Sleep Initiation and Maintenance Disorders4
Back Pain3

Trials

Showing 1 to 25 of 112. Each trial links to its page on Pharma Observatory.

12 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.